click below
click below
Normal Size Small Size show me how
Pharm Chapter17
Drug Addiction
Question | Answer |
---|---|
MOA disulfiram | Aldehyde dehydrogenase inhibitor |
Clinical applications disulfiram | Alcoholism |
Coadministration of what with disulfiram can result in adverse CNS effects? | Isoniazid |
Facial flushing, headache, nausea, vomiting, weakness, orthostatic hypotension, respiratory difficulty? | Acetaldehyde accumulation due to disulfiram |
Opioid antagonists | Naloxone, Naltrexone |
MOA Naloxone, Naltrexone | Block binding of opiods to mu-opioid receptor |
Clinical applications naloxone | Opioid overdose, Rapid reversal of opioid toxicity |
Clinical applications naltrexone | Opioid dependence, Alcohol dependence |
Long Lasting Opiod Agonist? | Methadone |
MOA methadone | Binds and activated mu-opioid receptor |
Clinical applications methadone | Opioid detoxification, Severe pain |
Coadministration with what may decrease serum methadone concentration and lead to methadone withdrawal symptoms? | Phenytoin |
Opioid partial agonist? | Buprenorphine |
MOA Buprenorphine | Partial mu-opioid receptor agonist, and kappa-opioid receptor antagonist |
Clinical applications buprenorphine | Opioid dependence, Moderate to severe pain |
Sublingual preparation of buprenorphine? | Suboxone, contains naloxone, to block effects of buprenorphine if parenterally administered |
Gaba-ergic agonist? | Acamprosate |
MOA acamprosate? | Stimulates inhibitory GABAergic neurotransmission in the brain and antagonizes the effects of glutamate. |
Clinical application acamprosate | Maintenance of abstinence in alcoholism |